PDF(Pubmed)
Abstract：
Large-cell neuroendocrine carcinoma (LCNEC) is a rare subtype of non-small-cell lung cancer associated with a poor prognosis. LCNEC is genetically heterogeneous, and studies have revealed distinct molecular subtypes of LCNEC, which may have therapeutic implications. Herein, we present a case of a patient with stage IV LCNEC harboring a KIF5B-RET fusion whose disease responded to the selective RET inhibitor selpercatinib both extra- and intra-cranially, highlighting the importance of comprehensive molecular testing in LCNEC for selection of optimal treatment.
摘要：
大细胞神经内分泌癌（LCNEC）是非小细胞肺癌的一种罕见亚型，预后不良。LCNEC是基因异质性的，研究揭示了LCNEC的不同分子亚型，可能有治疗意义。在这里，我们介绍了一例患有IV期LCNEC的患者，该患者患有KIF5B-RET融合，其疾病对选择性RET抑制剂selpercatinib有反应，无论是颅外还是颅内，强调在LCNEC中进行全面分子检测对于选择最佳治疗方法的重要性。
